Transsulfuration pathway: a targeting neuromodulator in Parkinson’s disease
暂无分享,去创建一个
M. Gonsebatt | Gabriela Figueroa-González | V. Campos-Peña | L. Quintas-Granados | D. Silva-Adaya | C. Trejo‐Solís | V. J. Hernández-Abad | Edgar Yebrán Villegas-Vázquez | Andrea Corona-Trejo | Octavio Daniel Reyes-Hernández | E. Y. Villegas-Vázquez
[1] K. Sriram,et al. Molecular Mechanisms Underlying Neuroinflammation Elicited by Occupational Injuries and Toxicants , 2023, International journal of molecular sciences.
[2] T. Ezike,et al. Volatile organic compounds: A proinflammatory activator in autoimmune diseases , 2022, Frontiers in Immunology.
[3] A. Garcia-Serrano,et al. Taurine Supplementation as a Neuroprotective Strategy upon Brain Dysfunction in Metabolic Syndrome and Diabetes , 2022, Nutrients.
[4] T. Bottiglieri,et al. One-Carbon Metabolism in Alzheimer’s Disease and Parkinson’s Disease Brain Tissue , 2022, Nutrients.
[5] Nektarios Tavernarakis,et al. One-Carbon Metabolism: Pulling the Strings behind Aging and Neurodegeneration , 2022, Cells.
[6] I. Y. Iskusnykh,et al. Glutathione in Brain Disorders and Aging , 2022, Molecules.
[7] M. Asanuma,et al. Glutathione and Related Molecules in Parkinsonism , 2021, International journal of molecular sciences.
[8] Ray-Jade Chen,et al. Exercise renovates H2S and Nrf2-related antioxidant pathways to suppress apoptosis in the natural ageing process of male rat cortex , 2021, Biogerontology.
[9] S. Yao,et al. Direct Quantification and Visualization of Homocysteine, Cysteine, and Glutathione in Alzheimer's and Parkinson's Disease Model Tissues. , 2021, Analytical chemistry.
[10] D. Spandidos,et al. Protective role of taurine against oxidative stress , 2021, Molecular medicine reports.
[11] A. Tawfik,et al. Homocysteine and Age-Related Central Nervous System Diseases: Role of Inflammation , 2021, International journal of molecular sciences.
[12] K. Aoyama. Glutathione in the Brain , 2021, International journal of molecular sciences.
[13] B. Paul. Neuroprotective Roles of the Reverse Transsulfuration Pathway in Alzheimer’s Disease , 2021, Frontiers in Aging Neuroscience.
[14] Ke Wang,et al. Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson's disease model through inhibition of microglial activation. , 2021, Neurotoxicology.
[15] Haijun Li,et al. Role of homocysteine in the development and progression of Parkinson’s disease , 2020, Annals of clinical and translational neurology.
[16] M. Peana,et al. The glutathione system in Parkinson’s disease and its progression , 2020, Neuroscience & Biobehavioral Reviews.
[17] F. Al Mutairi. Hyperhomocysteinemia: Clinical Insights , 2020, Journal of central nervous system disease.
[18] Rana Muhammad Aadil,et al. Cysteine and homocysteine as biomarker of various diseases , 2020, Food science & nutrition.
[19] N. Syed,et al. Taurine Promotes Neurite Outgrowth and Synapse Development of Both Vertebrate and Invertebrate Central Neurons , 2020, Frontiers in Synaptic Neuroscience.
[20] J. Jankovic,et al. Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] P. Huang,et al. Hydrogen Sulfide and Endoplasmic Reticulum Stress: A Potential Therapeutic Target for Central Nervous System Degeneration Diseases , 2020, Frontiers in Pharmacology.
[22] C. Szabó,et al. Potential role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H2S) pathway in cancer cells. , 2020, Pharmacological research.
[23] M. Okun,et al. Diagnosis and Treatment of Parkinson Disease: A Review. , 2020, JAMA.
[24] Patrik Brundin,et al. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. , 2020, Clinics in geriatric medicine.
[25] Xiangyang Zhu,et al. Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease , 2019, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.
[26] Ronan M. T. Fleming,et al. Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson’s Disease , 2019, Cell reports.
[27] Rubaiya Tabassum,et al. Potential for therapeutic use of hydrogen sulfide in oxidative stress-induced neurodegenerative diseases , 2019, International journal of medical sciences.
[28] M. Repici,et al. DJ-1 in Parkinson’s Disease: Clinical Insights and Therapeutic Perspectives , 2019, Journal of clinical medicine.
[29] Chaoran Chen,et al. Roles of taurine in cognitive function of physiology, pathologies and toxication. , 2019, Life sciences.
[30] F. Mastaglia,et al. Elevated Serum Homocysteine Levels Have Differential Gender-Specific Associations with Motor and Cognitive States in Parkinson's Disease , 2019, Parkinson's disease.
[31] D. Choi,et al. Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms , 2019, Redox biology.
[32] S. Snyder,et al. Regulators of the transsulfuration pathway , 2018, British journal of pharmacology.
[33] M. De la Fuente,et al. Lymphoproliferation Impairment and Oxidative Stress in Blood Cells from Early Parkinson’s Disease Patients , 2019, International journal of molecular sciences.
[34] Guanghui Wang,et al. Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration. , 2019, ACS chemical neuroscience.
[35] Hong-Mei Diao,et al. Association Between MTHFR Genetic Polymorphism and Parkinson’s Disease Susceptibility: A Meta-analysis , 2019, Open medicine.
[36] R. Sandhir,et al. Hydrogen sulfide attenuates homocysteine-induced neurotoxicity by preventing mitochondrial dysfunctions and oxidative damage: In vitro and in vivo studies , 2018, Neurochemistry International.
[37] Siyuan Li,et al. Protective effects of taurine against inflammation, apoptosis, and oxidative stress in brain injury , 2018, Molecular medicine reports.
[38] V. Jakovljevic,et al. Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems. , 2018, Canadian journal of physiology and pharmacology.
[39] S. Chirumbolo,et al. Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. , 2018, Current medicinal chemistry.
[40] S. Snyder,et al. Cysteine Metabolism in Neuronal Redox Homeostasis. , 2018, Trends in pharmacological sciences.
[41] Yanzhang Li,et al. Hydrogen sulfide and autophagy: A double edged sword , 2018, Pharmacological research.
[42] Xiaofang Liu,et al. Taurine protects dopaminergic neurons in a mouse Parkinson’s disease model through inhibition of microglial M1 polarization , 2018, Cell Death & Disease.
[43] Liyan Hou,et al. Taurine protects noradrenergic locus coeruleus neurons in a mouse Parkinson’s disease model by inhibiting microglial M1 polarization , 2018, Amino Acids.
[44] L. Bobermin,et al. Homocysteine Induces Glial Reactivity in Adult Rat Astrocyte Cultures , 2017, Molecular Neurobiology.
[45] J. Bian,et al. Impaired CBS-H2S signaling axis contributes to MPTP-induced neurodegeneration in a mouse model of Parkinson’s disease , 2018, Brain, Behavior, and Immunity.
[46] S. Snyder,et al. Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. , 2017, Biochemical pharmacology.
[47] T. Montine,et al. Homocysteine and cognitive function in Parkinson's disease. , 2017, Parkinsonism & related disorders.
[48] Xiaohu Zhang,et al. GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson’s Disease , 2017, Front. Pharmacol..
[49] Wei-guo Yin,et al. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats , 2017, Neuroscience Letters.
[50] Chao-shu Tang,et al. H2S-Induced Sulfhydration: Biological Function and Detection Methodology , 2017, Front. Pharmacol..
[51] S. Williams,et al. Glutathione in the human brain: Review of its roles and measurement by magnetic resonance spectroscopy. , 2017, Analytical biochemistry.
[52] Anthony R. White,et al. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease , 2017, Neurochemistry International.
[53] J. Bian,et al. A New Hope for a Devastating Disease: Hydrogen Sulfide in Parkinson’s Disease , 2017, Molecular Neurobiology.
[54] T. Yoldas,et al. Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease , 2017, Neurological Sciences.
[55] O. Tysnes,et al. Epidemiology of Parkinson’s disease , 2017, Journal of Neural Transmission.
[56] Jian Li,et al. Involvement of microRNA-135a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson's Disease , 2016, Cellular Physiology and Biochemistry.
[57] Anupom Borah,et al. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. , 2016, Biochimica et biophysica acta.
[58] N. Tyagi,et al. Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer’s Disease-Like Pathology, Blood–Brain Barrier Disruption, and Synaptic Disorder , 2016, Molecular Neurobiology.
[59] H. Deng,et al. Association of the MTHFR rs1801131 and rs1801133 variants in sporadic Parkinson’s disease patients , 2016, Neuroscience Letters.
[60] N. Nagahara,et al. Identification of H2S3 and H2S produced by 3-mercaptopyruvate sulfurtransferase in the brain , 2015, Scientific Reports.
[61] Yongsheng Yuan,et al. Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment , 2015, The International journal of neuroscience.
[62] P. Canto,et al. Association of the rs1801133 variant in the MTHFR gene and sporadic Parkinson's disease. , 2015, Folia neuropathologica.
[63] S. Snyder,et al. Modes of physiologic H2S signaling in the brain and peripheral tissues. , 2015, Antioxidants & redox signaling.
[64] P. Hrelia,et al. Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease , 2014, Brain Research.
[65] Takashi Ito,et al. Tissue Depletion of Taurine Accelerates Skeletal Muscle Senescence and Leads to Early Death in Mice , 2014, PloS one.
[66] J. Jia,et al. Downregulation of cystathionine β-synthase/hydrogen sulfide contributes to rotenone-induced microglia polarization toward M1 type. , 2014, Biochemical and biophysical research communications.
[67] Phil Hyu Lee,et al. Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow‐mediated dilation study , 2014, Movement disorders : official journal of the Movement Disorder Society.
[68] B. Tang,et al. Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease , 2014, Journal of the Neurological Sciences.
[69] Seung Yong Park,et al. Development of a Novel Cysteine Sulfinic Acid Decarboxylase Knockout Mouse: Dietary Taurine Reduces Neonatal Mortality , 2014, Journal of amino acids.
[70] H. Cho,et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). , 2013, Archives of gerontology and geriatrics.
[71] B. Viskolcz,et al. Glutathione – Hydroxyl Radical Interaction: A Theoretical Study on Radical Recognition Process , 2013, PloS one.
[72] M. Smeyne,et al. Glutathione metabolism and Parkinson's disease. , 2013, Free radical biology & medicine.
[73] Debabrata Sen,et al. A ratiometric two-photon fluorescent probe reveals reduction in mitochondrial H2S production in Parkinson's disease gene knockout astrocytes. , 2013, Journal of the American Chemical Society.
[74] N. Khaper,et al. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. , 2013, Antioxidants & redox signaling.
[75] A. Sparatore,et al. Therapeutic Effect of Hydrogen Sulfide-Releasing L-Dopa Derivative ACS84 on 6-OHDA-Induced Parkinson’s Disease Rat Model , 2013, PloS one.
[76] S. Snyder,et al. Sulfhydration mediates neuroprotective actions of parkin , 2013, Nature Communications.
[77] T. Guilarte,et al. Manganese exposure induces α-synuclein aggregation in the frontal cortex of non-human primates. , 2013, Toxicology letters.
[78] David N Hauser,et al. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism , 2013, Neurobiology of Disease.
[79] A. Schapira,et al. α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease , 2013, Molecular Neurobiology.
[80] Juan Tang,et al. The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels. , 2012, Antioxidants & redox signaling.
[81] M. Gonsebatt,et al. The role of amino acid transporters in GSH synthesis in the blood–brain barrier and central nervous system , 2012, Neurochemistry International.
[82] Jang-Yen Wu,et al. Beneficial effect of taurine on hypoxia- and glutamate-induced endoplasmic reticulum stress pathways in primary neuronal culture , 2012, Amino Acids.
[83] S. Budrewicz,et al. The Impact of MRI White Matter Hyperintensities on Dementia in Parkinson's Disease in Relation to the Homocysteine Level and Other Vascular Risk Factors , 2012, Neurodegenerative Diseases.
[84] J. Bian,et al. Hydrogen sulfide protects SH-SY5Y cells against 6-hydroxydopamine-induced endoplasmic reticulum stress. , 2012, American journal of physiology. Cell physiology.
[85] G. Ghanem,et al. Has removal of excess cysteine led to the evolution of pheomelanin? , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.
[86] Wei Zheng,et al. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. , 2012, Pharmacology & therapeutics.
[87] S. Bearden,et al. Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptor-dependent regulation of adherens and tight junctions. , 2011, Blood.
[88] M. Kaneki,et al. Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. , 2011, Antioxidants & redox signaling.
[89] A. Hayashi‐Takagi,et al. Glutathione is a physiologic reservoir of neuronal glutamate. , 2011, Biochemical and biophysical research communications.
[90] Xiao-Qing Tang,et al. Inhibition of Hydrogen Sulfide Generation Contributes to 1-Methy-4-Phenylpyridinium Ion-Induced Neurotoxicity , 2011, Neurotoxicity Research.
[91] G. Jameson,et al. Iron, cysteine and Parkinson’s disease , 2011 .
[92] T. Chin,et al. Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[93] S. Tsuji,et al. CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease , 2010, PloS one.
[94] J. Bian,et al. Protective effect of hydrogen sulphide against 6‐OHDA‐induced cell injury in SH‐SY5Y cells involves PKC/PI3K/Akt pathway , 2010, British journal of pharmacology.
[95] Marc Cruts,et al. Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.
[96] P. Hluštík,et al. Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients , 2010, Neurological Sciences.
[97] J. Bian,et al. Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models , 2010, Aging cell.
[98] Chaur-Jong Hu,et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients , 2009, Journal of the Neurological Sciences.
[99] U. Dillmann,et al. Methylation status and neurodegenerative markers in Parkinson disease. , 2009, Clinical chemistry.
[100] Zhi-Sheng Jiang,et al. Hydrogen sulfide inhibits MPP(+)-induced apoptosis in PC12 cells. , 2009, Life sciences.
[101] T. Müller,et al. Peripheral COMT inhibition prevents levodopa associated homocysteine increase , 2009, Journal of Neural Transmission.
[102] J. Obeso,et al. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study , 2009, Movement disorders : official journal of the Movement Disorder Society.
[103] Ying Jin,et al. Protective function of taurine in glutamate‐induced apoptosis in cultured neurons , 2009, Journal of neuroscience research.
[104] C. Vargas,et al. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson´s disease , 2009, Metabolic Brain Disease.
[105] Norihiro Shibuya,et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. , 2009, Antioxidants & redox signaling.
[106] P. Wong,et al. Hydrogen Sulfide Inhibits Rotenone-Induced Apoptosis via Preservation of Mitochondrial Function , 2009, Molecular Pharmacology.
[107] M. Beal,et al. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.
[108] J. Andersen,et al. Oxidative and nitrative protein modifications in Parkinson's disease. , 2008, Free radical biology & medicine.
[109] G. Nappi,et al. Homocysteine and Parkinson's disease: A dangerous liaison? , 2007, Journal of the Neurological Sciences.
[110] V. Ravindranath,et al. Inhibition of cystathionine-γ-lyase leads to loss of glutathione and aggravation of mitochondrial dysfunction mediated by excitatory amino acid in the CNS , 2007, Neurochemistry International.
[111] R. Franco,et al. The central role of glutathione in the pathophysiology of human diseases , 2007, Archives of physiology and biochemistry.
[112] K. Hasan,et al. Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease , 2006, Clinical Neuroscience Research.
[113] M. Krajinovic,et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy , 2006, Journal of the Neurological Sciences.
[114] B. Winblad,et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease , 2006, Neuroscience Letters.
[115] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[116] Y. Terayama,et al. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. , 2005, Life sciences.
[117] Eun-Sook Y. Lee,et al. Effects of homocysteine on the dopaminergic system and behavior in rodents. , 2005, Neurotoxicology.
[118] P. Livrea,et al. Hyperhomocysteinemia in l‐dopa treated Parkinson's disease patients: effect of cobalamin and folate administration , 2005, European journal of neurology.
[119] Ying Jin,et al. Mode of action of taurine as a neuroprotector , 2005, Brain Research.
[120] P. Livrea,et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. , 2005, Parkinsonism & related disorders.
[121] P. Livrea,et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients , 2005, Movement disorders : official journal of the Movement Disorder Society.
[122] S. Özkan,et al. Plasma Homocysteine Levels in Pergolide-Treated Parkinson Disease Patients , 2004, Clinical neuropharmacology.
[123] M. Brosnan,et al. Methylation demand: a key determinant of homocysteine metabolism. , 2004, Acta biochimica Polonica.
[124] J. Troncoso,et al. S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.
[125] D. Twelves,et al. Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[126] M. Mattson,et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.
[127] Barry Halliwell,et al. Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.
[128] R. B. Parsons,et al. Cysteine dioxygenase: Regional localisation of protein and mRNA in rat brain , 2001, Journal of neuroscience research.
[129] J. B. Justice,et al. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter , 2001, Journal of neurochemistry.
[130] J. Hirrlinger,et al. Glutathione metabolism in brain , 2000 .
[131] K. Tipton,et al. Taurine‐Induced Attenuation of MPP+ Neurotoxicity In Vitro , 2000, Journal of neurochemistry.
[132] H. Jakubowski. Calcium-dependent Human Serum Homocysteine Thiolactone Hydrolase , 2000, The Journal of Biological Chemistry.
[133] L. Elferink,et al. Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.
[134] K. Jellinger,et al. The Role of Iron in Neurodegeneration , 1999, Drugs & aging.
[135] H. Przuntek,et al. Elevated Plasma Levels of Homocysteine inParkinson’s Disease , 1998, European Neurology.
[136] A. Lees,et al. Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.
[137] T. Montine,et al. Neurotoxicity of Endogenous Cysteinylcatechols , 1997, Experimental Neurology.
[138] G. Dryhurst,et al. Irreversible Inhibition of Mitochondrial Complex I by 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1): A Putative Nigral Endotoxin of Relevance to Parkinson's Disease , 1997, Journal of neurochemistry.
[139] S. Aquilonius,et al. Levels ofl-MethionineS-Adenosyltranferase Activity in Erythrocytes and Concentrations ofS-Adenosylmethionine andS-Adenosylhomocysteine in Whole Blood of Patients with Parkinson's Disease , 1997, Experimental Neurology.
[140] B. Shukitt-Hale,et al. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. , 1997, Clinical neuropharmacology.
[141] L. Ahtee,et al. Intrastriatal taurine increases striatal extracellular dopamine in a tetrodotoxin-sensitive manner in rats , 1996, Neuroscience Letters.
[142] G. Dryhurst,et al. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. , 1996, Chemical research in toxicology.
[143] G. Omenn,et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.
[144] M. Marmot,et al. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? , 1995, Journal of neurology, neurosurgery, and psychiatry.
[145] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[146] T. Weimbs,et al. Proteolipid protein (PLP) of CNS myelin: positions of free, disulfide-bonded, and fatty acid thioester-linked cysteine residues and implications for the membrane topology of PLP. , 1992, Biochemistry.
[147] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[148] M. Palkovits,et al. Taurine Levels in Discrete Brain Nuclei of Rats , 1986, Journal of neurochemistry.
[149] K. Kuriyama,et al. Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration , 1986, Acta neurologica Scandinavica.
[150] A. Meister,et al. Transport of gamma-glutamyl amino acids: role of glutathione and gamma-glutamyl transpeptidase. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[151] D. Straughan,et al. Synaptic mechanisms in the substantia nigra , 1976, The Journal of pharmacy and pharmacology.
[152] Dennis W Dickson,et al. Neuropathology of Parkinson disease. , 2018, Parkinsonism & related disorders.
[153] J. Volkmann,et al. Parkinson disease , 2017, Nature Reviews Disease Primers.
[154] K. Hensley,et al. Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagement. , 2015, Free radical biology & medicine.
[155] Xiao-Qing Tang,et al. Neuroprotective effects of hydrogen sulfide and the underlying signaling pathways , 2015, Reviews in the neurosciences.
[156] A. Antonini,et al. The MTHFR C677T polymorphism modifies age at onset in Parkinson’s disease , 2013, Neurological Sciences.
[157] Jang-Yen Wu,et al. Taurine and central nervous system disorders , 2012, Amino Acids.
[158] Y. Goto,et al. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. , 2010, Antioxidants & redox signaling.
[159] Wen-Jing Li 李文静,et al. Dose- and time-dependent α-synuclein aggregation induced by ferric iron in SK-N-SH cells , 2010, Neuroscience Bulletin.
[160] Yu Chen,et al. The potential protective effects of taurine on coronary heart disease. , 2010, Atherosclerosis.
[161] Chih-min Yang,et al. Synergistic effects of homocysteine, S‐adenosylhomocysteine and adenosine on apoptosis in BV‐2 murine microglial cells , 2008, BioFactors.
[162] P. Blumbergs,et al. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies , 2008, Acta Neuropathologica.
[163] M. Brosnan,et al. Methylation demand and homocysteine metabolism. , 2004, Advances in enzyme regulation.
[164] R. Diaz-Arrastia,et al. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. , 2003, Archives of neurology.
[165] R. Wolfe,et al. Homocysteine metabolism. , 1999, Annual review of nutrition.
[166] W. Tatton,et al. Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.
[167] D. Hoffman,et al. Relationship between tissue levels of S-adenosylmethionine, S-adenylhomocysteine, and transmethylation reactions. , 1979, Canadian journal of biochemistry.